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THE PHARMACEUTICAL INDUSTRY:
A Pharmacy Student’s Guide
Christian Egly, PharmD Candidate, and Yaman Kaakeh, PharmD, 
BCPS, BCNSP, CNSC, BCCCP, College of Pharmacy
INTRODUCTION AND BACKGROUND 
WITH LITERATURE REVIEW
Pharmaceutical industry positions and job descriptions 
are largely unknown to pharmacy students. A recent 
article showed that pharmacy students are aware of 
postgraduate training programs, such as fellowships; 
however, evidence shows students do not receive enough 
information about industry career opportunities while 
in pharmacy school (Audette, McGann, Horton, & 
Silva, 2014; Shpilfogel, Tyrrell, & Alexander, 2015a; 
Yung, Johal, & Pan, 2004). Despite a lack of knowledge 
about career opportunities, the number of fellowship 
positions fi lled each year has grown signifi cantly. The 
current number of fellowships occupied by pharmacists 
is approaching 450—an increase from 250 positions four 
years prior (Alexander, Dipsia, Wells, & Singh, 2018). 
Departments included under fellowships are medical 
aff airs, regulatory aff airs, clinical research and develop-
ment, commercial, health outcomes research, and more. 
The primary purpose of this article is to describe how 
a career in industry is benefi cial to a variety of con-
stituents, including patients, health care providers, and 
students. A secondary purpose is to highlight ten pri-
mary industry positions for pharmacists. By detailing a 
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personal experience in industry, other pharmacy students 
can have a better glimpse of a unique career path and 
what this type of work involves. 
METHODOLOGY
The Industry Pharmacist Organization (IPhO), the 
Rutgers Fellowship Brochure (Rutgers, 2017), and other 
sources were utilized to summarize ten pharmaceutical 
industry positions for pharmacists. Details of the diff er-
ent areas can be found in Table 1. In addition, depending 
on the company, some jobs may integrate multiple 
departments; for example, medical information and 
medical aff airs positions have multiple similarities.
Departments with the most fellowship positions fi lled by 
pharmacists as of 2018 are medical aff airs followed by 
regulatory aff airs (Alexander et al., 2018). Opportunities, 
besides those mentioned, within early clinical development 
include clinical pharmacology and translational medicine. 
Students with an interest in pharmacokinetics/pharmaco-
dynamics (PK/PD) should look into clinical pharmacology 
(Goh, Alrawi, & Lozito, 2006). Translational medicine 
would involve bench to bedside research integrating both 
basic science and clinical research aspects. Firsthand expe-
rience seems to be the ideal way for pharmacy students to 
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understand industry positions. My own personal experience 
at Kashiv Pharma, LLC can be seen in the next section.
STUDENT EXPERIENCE
Kashiv Pharma is located in Bridgewater, New Jersey. 
The company specializes in 505(b)2 products, which 
is an accelerated approval pathway for reformulations 
of current drugs. For instance, a product approved, but 
dosed four times a day, has the potential to be refor-
mulated. Reformulating the product could allow for 
once-daily dosing and would benefit patients in terms 
of compliance, better pharmacokinetics, level of effec-
tiveness, or improved safety profile. I will explain my 
experience from working in the market research or busi-
ness development sector as a rotation student and intern.
Daily responsibilities included reading clinical trials, 
utilizing Intercontinental Marketing Services (IMS) data 
for prescription volume and sales, scanning patents, 
searching for other drugs in development using a pro-
gram called PharmaCircle™, and utilizing various other 
sources. After compiling the information, I would make 
a document summarizing the data in order to explain the 
information to other people in the company. Final steps 
would be to determine whether the product concept was 
worth pursuing or if it should be abandoned.
Here is an example of how a typical product would be 
evaluated. Let’s call the drug Product X. Product X 
is currently dosed three to four times per day and has 
adverse side effects. Using IMS data, the product had 12 
million prescriptions written last year and $360 million 
in sales, which tells us there is a good market for the 
drug. Next, looking at clinical trial information and the 
package insert can give us detailed clinical information 
about the product. Questions to answer include:
1. What does the PK/PD profile look like? 
2. How effective is the medication?
3. Has there been an extended release product in 
clinical development before?
4. What does the safety profile look like?
5. Are side effects related to peak/trough 
concentrations of the drug?
Answering these questions starts to delineate the product 
concept, which would give an impression whether Prod-
uct X is capable of being improved or not.
Some surprising facts can come from a literature review. 
For instance, a few articles showed that extended release 
products previously existed for certain medications we 
were evaluating. The extended release product was even 
superior to the immediate release, but for unknown rea-
sons, it was discontinued during development or in the 
post-market phase. If discontinuation occurs, it is impor-
tant to determine the root cause. Was the profit from the 
drug not enough to sustain development? Did a company 
acquire a more important project? These are important 
questions to ask.
Once clinical trials, IMS data, and package insert data 
have been scoured, the competitive atmosphere must be 
Figure 1. A snapshot of typical Pharmacircle information for the drug clopidogrel. The site gives 
different phases of drug development and other information.
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Position Title Main Roles Detailed Responsibilities
Early Phase Clinical 
Development
Phase I–Phase IIa 
clinical trials
1. Manage trials 
2. Evaluate study protocols 
3. Summarize trial findings in reports 
4. Select and collaborate with trial site, Contract Research 
Organizations (CROs) 
5. Safety, tolerability, Pharmacokinetics/Pharmacodynamics (PK/
PD), drug-drug and drug-food interactions, dosing, and pilot 
efficacy
Late Phase Clinical 
Development
Phase IIb–Phase IV 
clinical trials
1. Manage trials 
2. Evaluate study protocols 
3. Select and collaborate with trial site, Contract Research 
Organizations (CROs) 
4. Summarize trial findings in reports 




Sales and product 
advertising material 
production
1. Oversee marketing materials by participating in medical and legal 
peer review committee 
2. Manage expenditures of marketing and determine return on 
investment (ROI) 
3. Collaborate with market research/business analytics department 






information related to 
product
1. Respond to information requests about a product from patients, 
families, physicians, etc. 
2. Formulate database with responses to medical inquiries 
3. Review promotional materials 
4. Plan educational materials through collaboration with Key Opinion 
Leaders (KOLs), managed care and academia
Regulatory Affairs
Communications 
with FDA and other 
regulatory agencies
1. Regulatory communications throughout development of a product 
(discovery to post-marketing studies) 
2. Document production and analysis 
 • Investigational New Drug (IND) 
 • New Drug Application (NDA) 
3. Review/revise product labeling 
4. Review/revise advertising and promotional materials to ensure 
complies with regulations 
5. Consult with preclinical and clinical studies to ensure data 





1. Maintain relationships with medical experts in specific therapeutic 
area within a geographic area 
 • Education for clinicians and sales force 
 • Communicate with internal stakeholders 
 • Relationships with managed market teams 
2. Involves 60–80% travel time 
 • Travel to hospitals or CRO sites for clinical trials (training 
    and communication) 
3. Ensures compliance for credentialing of trial sites (background 
checks, medical testing (i.e., Tuberculosis test) and immunization 
verification, training on facility policies, HIPPA agreements, etc.) 
4. Development of educational materials
Table 1. Results: Industry positions and responsibilities for pharmacists.








1. Establishing relationships with medical directors, MSLs, KOLs, 
and health outcomes/economics researchers 
2. Provide transparency for ongoing trials, milestones, and other 
pertinent information through annual reports and news blurbs to: 
 • Internal and external stakeholders 
 • Customers 
 • Prescribers 
3. Bridge between research and discovery to commercialization 
4. Present educational materials about products or therapeutic 
landscape 
5. Provide support for clinical studies in off-label indications






1. Monitor, assess, and evaluate safety profile of product throughout 
lifecycle 
2. Submit documents summarizing safety profile and concerns, 
including: 
 • Annual reports 
 • Investigational brochures 
 • Risk assessments 
 • Risk management plans (RMPs) 
 • Risk Evaluation Mitigation Safety (REMS) 
3. Anticipate regulatory problems with safety assessments and 
develop ways to deal with the concerns 







1. Provide proof of product’s market value for medical intervention 
(device or medication), which can be used for: 
 • Market access 
 • Pricing 
 • Formulary decisions 
 • National/international clinical guidelines 
2. Support market and sales teams by utilizing publications, Quality 
of Life (QOL), Quality Adjusted Life Years (QALYs), health care 
models, etc. 
3. Publish and present health outcomes research 





needs in medical 
community and 
financial incentives 
of developing certain 
products
1. Evaluate market trends, utilize internal and external relationships, 
and analyze clinical data to identify opportunities to add to company’s 
portfolio 
2. Determine whether to keep certain activities within the company or 
outsource to contract organizations 
3. Collaborate with medical affairs, intellectual property (legal), 
regulatory affairs, marketing, HEOR, and managed markets 
4. Ensure internal stakeholders’ views align with external stakeholders 
to uphold appropriate return on investment and mutual benefits
Table 1. (Continued)
evaluated. What other products for the disease state are 
already on the market or in clinical development? Phar-
macircle™ is a database that can show the current stage of 
development for a medication, which is particularly useful 
for evaluation of competitors. For example, Pharmacir-
cle™ shows whether a product is in preclinical, clinical 
trial phases (I–IV), on the market, or has been discontin-
ued. The software also includes links to the websites of 
the companies that manufacture the drug. Important infor-
mation from company websites includes news articles or 
annual reports highlighting the progress of the medication. 
In some instances, PharmaCircle™ may show that a drug 
is still in clinical development. However, the company 
website may have a recent press release showing negative 
results of the most recent trial. The assumption is that the 
drug would likely be discontinued.
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Patents help to understand if a certain technology or 
formulation has already been assessed. For instance, one 
of the products Kashiv evaluated was initially unstable. 
An outside researcher came to Kashiv for a partner-
ship, claiming he had invented a technology that gave a 
stable formulation. He also claimed the formulation was 
completely novel. After searching patents, it was discov-
ered that two to three other formulations existed and had 
patents for the same product. Not only were there patents 
for stable formulations of the drug, but a similar prod-
uct was already marketed in Germany. The person who 
came to the company asking for a partnership did not 
have their own patent at the time.
After data has been gathered from IMS, clinical trials, 
package inserts, PharmaCircle™, and elsewhere, the 
next steps could be taken, which involve external assess-
ments of the product concept. These include talking 
with key opinion leaders (KOLs), submitting surveys 
to clinicians that use the current medication in practice, 
and contracting with other market research firms for 
discussions with pharmacy benefit managers (PBMs). 
Discussions with PBMs evaluate the likelihood that the 
new formulation of Product X will be covered by insur-
ance. Talks with KOL’s usually involve a phone call to 
experts in the field. Generally, these are medical doctors 
who extensively prescribe the medication and may have 
been involved in published articles covering the drug 
in question. The phone call is important to understand, 
from a primary source, how often the medication is used 
and how the drug compares to other medications for the 
same indication. Most often, the information the medi-
cal doctor gives coincides with the original research; 
however, if their opinion differs significantly, further 
evaluation of the literature is necessary. Feedback from 
multiple physicians is important. Interviewing multiple 
KOL’s will generally give a good trend and help to see if 
there are outliers.
Market research surveys are sent to physicians. Kashiv 
uses a contract organization to deliver the surveys to 
multiple physicians (example n = 25). These surveys 
generally use Likert scales (ratings of 1–10) to gather 
information. Criteria assessed for the medication gener-
ally include clinical effectiveness, side effects, and how 
the medication compares to others that treat the same 
disease state. Eventually, the product concept (Product 
X) is discussed with the physicians taking the survey. 
Finally, the physicians evaluate the need for improve-
ment to the current formulation, how they believe 
reformulating will effect safety and efficacy, whether 
they think they would prescribe more of the drug after 
the reformulation, and so forth. Comparing survey data 
with data from existing clinical trials is important to 
ensure that the data matches. An example of conflicting 
evidence includes adverse event reporting in clinical tri-
als differing from the amount of adverse events reported 
by physicians in the surveys or phone calls.
Another aspect of market research involves discussing the 
product concept with pharmacy benefit managers (PBMs). 
If Product X will not be covered by insurance, the likeli-
hood of the product failing on the market increases. The 
same company that performs physician surveys is con-
tracted by Kashiv for market research with PBMs. The 
contract company will usually make phone calls or visits 
with PBMs to discuss the current product, other medica-
tions on the market, and the concept of Product X. The 
PBM will provide information on which tier the current 
drug is covered, a forecast for the tier that developed 
Product X will be placed into, and their estimation for the 
cost of the product. The data gathered is generally a rough 
estimate, but it’s important to determine w insurance com-
panies will likely think about Product X when the drug is 
marketed. From personal observation, it seems difficult to 
get PBMs to see the benefit of once-a-day prescriptions 
without further evidence. For this reason, clinical trials of 
505(b)2 products should aim to prove that Product X will 
be once a day and that it will improve the effectiveness 
and/or safety over the current formulation.
Figure 2. U.S. patent search results for amiodarone 
compositions. Notice not all results are directly related, but may 
only mention amiodarone formulations.
Tier Drug Type Cost (1, lowest– 5, highest)
1 Prefered Generics Minimal (1)
2 Generics Low (2)
3 Prefered Brands Medium (3)
4 Non-preferred High (4)
5 Specialty Max (5)
Table 2. Review of various tiers according to payer system, 
most ideal tier for approval would be tier 3. Preferred brands 
are mostly covered by insurance and take initial precedence in 
prescription utilization over tiers 4 and 5.
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Figure 4. 505(b)1 traditional NCE pathway vs 505(b)2 
reformulation pathway. (Courtesy of Stegemann et al.) 
Generally, the steps above are the majority of the work 
done in business development. Next steps include meet-
ing with members of the company to discuss market 
research data and to determine if Product X is a can-
didate for further development. If Product X is a good 
candidate, it will move on to the formulations team. 
Once a formulation is developed, the medication moves 
into clinical trials and to market, assuming success at 
each stage. Since the medication that Product X is based 
on is already on the market, the development process 
is generally much shorter than it is for a new chemical 
entity (NCE). The pathway for improved formulations is 
called the 505(b)2 pathway by the FDA. For NCEs the 
pathway follows a 505(b)1 route.
COMMUNITY IMPACT
Industry pharmacists’ impact on pharmaceutical devel-
opment could be largely beneficial to patients in the 
future. Products that pharmacists in industry develop 
could reduce pill burden, increase compliance, increase 
effectiveness, and reduce adverse effects associated with 
current therapies. By focusing on 505(b)2 products, 
the timeframe to bring these medications to market is 
greatly reduced compared to development of an NCE, 
allowing patients to access the medications sooner. 
Products evaluated at Kashiv Pharma cover patients in 
all age ranges so there is a large population that may be 
positively affected. Working with PBMs can allow for 
reduced prices of the medications to patients as well.
Improvement to medications not only impacts patients, 
but also the work of health care providers. Work in 
industry can profoundly impact health care systems, 
such as hospitals, long-term care facilities, and so forth. 
For instance, new medications could affect treatment 
guidelines for various disease states.
Other people potentially impacted by this article are 
pharmacy students. By sharing personal rotation and 
internship experiences, pharmacy students may benefit 
by having a glimpse into pharmaceutical industry work 
before having firsthand experiences.
STUDENT IMPACT
This article may give pharmacy students an opportunity 
to pursue further knowledge and understanding about the 
pharmaceutical industry. There is likely a lack of knowl-
edge about what industry positions can be filled and the 
general work requirements of each. A better understand-
ing exposes students to rewarding career options. Below 
are other pathways students can pursue to learn more 
about the pharmaceutical industry.
A couple of organizations specific to career paths in 
industry are the Industry Pharmacists Organization 
(IPhO) and the International Society for Pharmaceuti-
cal Engineering (ISPE). IPhO is specific to positions 
in industry that pharmacists usually take, which were 
summarized in the table earlier. The IPhO website 
provides information about professional development, 
fellowships, and careers, as well as published articles 
highlighting aspects of the pharmaceutical industry. 
Advanced pharmacy practice experiences (APPEs) are 
another great way to obtain experience in the pharma-
ceutical industry. Many pharmacy students in my class 
have enjoyed rotations at Eli Lilly. Purdue University 
also provides track rotation opportunities, which can be 
two- to three-month experiences at one pharmaceutical 
company. A rotation at the Food and Drug Administra-
tion (FDA) in Washington, DC, is another experience 
that would be valuable to students considering industry. 
The department of regulatory affairs is currently the 
second-largest fellowship by the number of pharmacists, 
which requires extensive FDA communication. Hav-
ing firsthand experience with the FDA might be viewed 
highly by companies when applying to Regulatory 
Affairs or other industry positions.
Internships are another pathway to obtain industry 
experience. My internship at Kashiv lasted two months, 
and I gained a considerable amount of knowledge dur-
ing that time. An internship provides early experience 
in positions that can be acquired after pharmacy school. 
Networking is key in industry, and having an internship 
starts to develop a student’s network.
Fellowships can also significantly help with network-
ing. The Rutgers pharmaceutical industry fellowship 
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has approximately 200 current fellows. Each fellow has 
an opportunity to meet others through weekly activities 
at Rutgers College of Pharmacy and other partnerships. 
Pharmacists can pursue a wide variety of positions, as high-
lighted by the information earlier. However, a fellowship is 
not a requirement to break into the pharmaceutical industry. 
In fact, only 20% of current industrial pharmacists com-
pleted a fellowship (Alexander et al., 2018). Many started 
out as clinicians and transferred to industry or went straight 
into industry from pharmacy school. Oftentimes fellow-
ships can provide an accelerated track to director roles.
Guest speakers and pharmacy school curriculum provide 
another avenue to learn about the pharmaceutical industry. 
Industry professionals occasionally come to speak about 
their work. One article evaluating 193 pharmacy students 
showed that 30% of students first learned about careers in 
the pharmaceutical industry from a guest speaker (Shpilfo-
gel, Tyrrell, & Alexander, 2015a). Other times, pharmacy 
schools will have electives that students can take to learn 
more about industry. One ten-week course at the Massachu-
setts College of Pharmacy and Health Sciences (MCPHS) 
covering industry showed a significant improvement in 
first-year pharmacy (P1) students’ knowledge across seven 
functional industry careers. The course improved student 
industry interest, from only 55% saying they were inter-
ested to 70% being interested in an industry career, and 
from 45% to 75% saying they had a specific area of interest 
by the end of the class (Audette et al., 2014).
CONCLUSION
Pharmacists are sought out for their broad clinical and 
scientific knowledge by pharmaceutical companies. This 
article touches on many of the different positions avail-
able to pharmacists through fellowships. There are several 
other industry positions besides those mentioned, such as 
manufacturing. Direct pharmaceutical experience through 
rotations, internships, or fellowships are important not only 
for training experiences, but also for building a professional 
network. In addition, joining pharmaceutical organiza-
tions such as IPhO and/or ISPE to meet peers interested in 
Figure 5. Note the difference in time for production between each pathway. (Courtesy of Camargo Pharmaceutical Services.)
industry helps, as involvement provides multiple network-
ing opportunities. I suggest taking pharmaceutical industry 
courses to understand more about the career opportunities. 
I hope my experiences provide a glimpse of responsibilities 
that a pharmacist may have in industry.
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